In Vivo Star Anti-Mouse CD370 / CD47 Bispecific Antibody

Cat # Size Price Quantity
5139011 mg$1750
5139025 mg$5950
51390325 mg$17850

Product Details


Clone10B4 / A4
ApplicationFunctional assay, animal model study
Host SpeciesCHO cells
ReactivityMouse
FormatLiquid
Target NameCD370, C-type lectin family member 9A, CD47, IAP, neurophilin, gp42, Integrin-associated protein
Product DescriptionIn Vivo Grade Recombinant Anti-mouse CD370 / CD47 Bispecific Antibody
IsotypeMouse IgG2c LALAPG Kappa
Antibody TypeRecombinant
Regulatory StatusRUO
Purity>95% by reducing SDS-PAGE
Endotoxin< 1 EU per 1 mg of the protein by the LAL method.
Storage Conditions4ºC
GradeIn vivo
Recommended UsageThis product is suitable for in vivo animal use. Optimal amounts need to be determined empirically for each experiment.
Research AreasConventional Dendritic cells (cDC1s), CD16 Monocytes
See All FormatsClone 10B4 / A4

Background Information


CD370, also known as CLEC9A (C-type lectin domain family 9 member A), is an endocytic receptor found predominantly on a specialized subset of dendritic cells known as CD141⁺ (BDCA3⁺) dendritic cells in humans. These cells play a key role in the immune system by cross-presenting antigens derived from dead or damaged cells on MHC class I molecules, thereby priming cytotoxic CD8⁺ T cell responses. Structurally, CD370 is a type II transmembrane protein that contains an extracellular C-type lectin-like domain and a short cytoplasmic tail with an immunoreceptor tyrosine-based activation motif (ITAM-like) that recruits SYK kinase upon ligand engagement. Functionally, CD370 recognizes actin filaments and other damage-associated molecular patterns (DAMPs) from necrotic cells, allowing dendritic cells to efficiently capture and process antigenic material from dying tissue or tumor cells. This makes CD370 an important target for strategies that seek to enhance antigen presentation and anti-tumor immunity.

CD47, in contrast, is a ubiquitously expressed transmembrane protein that acts as a critical regulator of the innate immune system. Often termed the “don’t eat me” signal, CD47 binds to its receptor, Signal Regulatory Protein Alpha (SIRPα), on macrophages and dendritic cells. This interaction inhibits phagocytosis and promotes immune evasion by preventing the clearance of cells expressing high levels of CD47. Many cancers exploit this pathway by overexpressing CD47, effectively shielding themselves from immune recognition and destruction. Blocking CD47–SIRPα signaling has therefore emerged as a powerful immunotherapeutic strategy to promote the phagocytic clearance of tumor cells and enhance anti-tumor immune activation.

A bispecific antibody targeting both CD370 and CD47 represents an innovative approach that synergizes immune activation with inhibition of immune suppression. By simultaneously binding CD47 on tumor cells and CD370 on dendritic cells, such a molecule could facilitate the efficient uptake and processing of cancer antigens while overcoming the “don’t eat me” brake imposed by CD47 signaling. This dual mechanism would ensure that tumor cell debris is effectively internalized, processed, and presented to T cells, leading to stronger and more durable anti-tumor immune responses. Moreover, focusing activation through CD370⁺ dendritic cells could concentrate the immunologic effects within tumor-draining lymphoid tissues, potentially minimizing systemic toxicities like anemia that can occur with traditional CD47 blockade. Thus, a CD370 × CD47 bispecific antibody could bridge the innate and adaptive immune systems, marking a promising new direction in cancer immunotherapy aimed at amplifying immune recognition and long-term tumor eradication.

Data Sheets


In Vivo Star Anti-Mouse CD370 / CD47 Bispecific Antibody TDS

Related Products


In Vivo Star Anti-Mouse CD370 (CLEC9A) Antibody, Clone 10B4

In Vivo Star Anti-Mouse CD370 / CD274 (PD-L1) Bispecific Antibody, Clone 10B4 / 10F.9G2

In Vivo Star Anti-Human CD47 Antibody, Clone B6H12

Frequently Asked Questions


What are In Vivo Star Biofunctional Antibodies?
In Vivo Star antibodies are premium-grade monoclonal antibodies purified and formulated specifically for use in animal studies. Each lot is manufactured under stringent quality controls to ensure the low endotoxin levels, high purity, and functional activity required for reliable in vivo results.

How are these antibodies different from standard research antibodies (e.g., for Western blot or flow cytometry)?
Standard research antibodies are optimized for in vitro detection assays and may contain preservatives, carrier proteins (like BSA), or higher endotoxin levels unsuitable for injection. In Vivo Star antibodies are formulated in injectable-grade, azide-free, low-endotoxin buffers and validated for functional bioactivity in living systems rather than just antigen binding.

What endotoxin and purity specifications do these antibodies meet?
All In Vivo Star antibodies are tested and certified to meet low-endotoxin thresholds (typically <1 EU/mg, lot-dependent) using the LAL (Limulus Amebocyte Lysate) assay, and are purified to ≥95% purity by SEC-HPLC or SDS-PAGE. Exact specifications are provided on the Certificate of Analysis (CoA) for each lot.

Are these antibodies azide-free and carrier-free?
All In Vivo Star antibodies are formulated without sodium azide and without carrier proteins such as BSA or gelatin, since both can interfere with animal physiology or immune readouts during in vivo studies.

Do you provide isotype controls?
Matched isotype control antibodies (same host species, isotype, and formulation) are available upon request for most clones to support proper experimental controls.

How should In Vivo Star antibodies be stored and handled?
Store at 4°C for short-term use and avoid repeated freeze-thaw cycles, which can reduce bioactivity; aliquoting is recommended for long-term storage per the product-specific storage instructions on the Certificate of Analysis. Always confirm storage conditions and expiration on the CoA that accompanies each lot, as these can vary slightly by antibody.

Have a product or application question? Consult our FAQs or contact us.